CASI pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, CASI pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
CASI pharmaceuticals: 11 sponsored US clinical trials, none currently recruiting.
CASI pharmaceuticals sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Cancer, with 2 trials.
Top-decile sponsor footprint
CASI pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
17 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
11 total, page 1 of 1
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
NCT02234986
Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
NCT01639248
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
NCT01104675
Study of ENMD-2076 in Patients With Multiple Myeloma
NCT00806065
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
NCT00658671
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
NCT00656461
Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
NCT00568646
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
NCT00481455
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
NCT00444314
Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer
NCT00394810
Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer
NCT00408226
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer
NCT00400348
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
NCT00328497
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
NCT00306618
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
NCT00306631
A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma
NCT00592579
Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer
NCT00049790
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 10 |
Therapeutic Areas
How the CASI pharmaceuticals early-phase archive is shaped
11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).
Phase mix: 0 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Advanced Cancer (2 trials), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
CASI pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
CASI pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 archived trials
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this CASI pharmaceuticals page
11 registered trials is a research-attention snapshot, not an endorsement of CASI pharmaceuticals or any single study.
- None of CASI pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Advanced Cancer is the condition CASI pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CASI pharmaceuticals pipeline card: 11 registered trials from official public datasets.Report a data error.